StockSelector.com
  Research, Select, & Monitor Tuesday, September 18, 2018 9:50:34 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$140.22$.26.19%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Johnson & Johnson vs Drug Manufacturers / Major

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.




Most of the firms here are multi-billion dollar companies that provide America and the world with a majority of the drugs they take on what is sometimes a daily basis. These companies usually have their own laboratories that design and develop new and innovative drugs for use in medicine. The research projects their own labs can not handle are typically contracted out to smaller clinical research firms who specialize in pharmaceuticals. Profit margins can be very high in this industry, which has helped fund the enormous amounts of research required to develop a new prescription drug.
 Totals Company Industry
  Sales: $76,450.0 Mil $351,659.0 Mil
  Market Cap: $380,873.1 Mil $1,500,183.4 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: 6.3% 6.1%
  Estimated Revenue: 6.2% 5.9%
  Historic Earnings: 8.5% 7.8%
  Estimated Earnings: 9.0% 5.8%
  Stock Price (1 Year): 4.1% 11.3%
  Cash per Share: (4.9%) (7.2%)
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: 16.3 16.6
  Price-to-Sales: 4.7 N/A
  Price-to-Book: 6.3 7.5
  Dividend Yield: N/A N/A
  Market Cap: $380,873.1 Mil $166,687.0 Mil
  Operations
  Net Margin: 26.4% 23.8%
  Gross Margin: 66.8% 69.5%
  Return on Equity: .0 .1
  Return on Assets: .0 .0
  Balance Sheet
  Current Ratio: 1.4 1.3
  Quick Ratio: 1.1 1.1
  Cash Ratio: .6 .5
  Debt-to-Equity: 1.6 3.3
  Interest Coverage: .0 .7
 Technicals
  Relative-Strength Index: 70.4 N/A

 Other companies in Drug Manufacturers / Major Price Market Cap
  Pfizer, Inc.  (PFE) $43.01 $255,995.5 Mil
  Novartis International AG  (NVS) $85.13 $199,715.0 Mil
  Merck & Co., Inc.  (MRK) $70.42 $189,852.3 Mil
  Abbott Laboratories  (ABT) $67.67 $119,708.2 Mil
  Eli Lilly & Co.  (LLY) $105.71 $108,903.5 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.